Evidence map›Paper›PMID 41352407›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2026

Pharmacokinetic and biodistribution (PK/BD) study of ProGel-Dex, a thermoresponsive dexamethasone prodrug for sustained joint pain relief in a mouse model of osteoarthritis.

Xin Wei, Gang Zhao, Xiaoke Xu, Zhenshan Jia, Devendra Kumar, Evan Glissmeyer, Daniel Tran, Haochen Jiang, Sumbal Talib, Ningrong Chen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xin WeiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Gang ZhaoEnsign Pharmaceutical, Inc, Omaha, NE, USA.
Xiaoke XuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Zhenshan JiaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Devendra KumarDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Evan GlissmeyerEnsign Pharmaceutical, Inc, Omaha, NE, USA.
Daniel TranEnsign Pharmaceutical, Inc, Omaha, NE, USA.
Haochen JiangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Sumbal TalibDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Ningrong ChenDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Zhulian WangEnsign Pharmaceutical, Inc, Omaha, NE, USA.
Yazen AlnoutiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Steven R GoldringEnsign Pharmaceutical, Inc, Omaha, NE, USA; Hospital for Special Surgery, New York, NY, USA.
Dong WangDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA; Ensign Pharmaceutical, Inc, Omaha, NE, USA. Electronic address: dwang@unmc.edu.

Funding

Nonaddictive opioid prodrug nanomedicine for musculoskeletal painR01AR080500 · NIAMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Dong Wang · 2022 to 2026
$2.3M
ProGel Technology for Better Management of Osteoarthritis PainR44DA051278 · NIDA · ENSIGN PHARMACEUTICAL, INC · PI GOLDRING, STEVEN · 2020 to 2022
$1.9M
N. Chen was supported by China Scholarship CouncilNIAMS NIH HHS R01 AR080500NIDA NIH HHS R44 DA051278
6 · The paper itself

Abstract

Intraarticular (IA) administration of ProGel-Dex was previously found to provide sustained joint pain relief with excellent safety in arthritis animal models. To explore ProGel-Dex' working mechanisms, we conducted a comprehensive pharmacokinetics/biodistribution (PK/BD) study of IA ProGel-Dex and the free Dex released in an osteoarthritis mouse model. An initial "burst" release and distribution of ProGel-Dex was observed in all organs/tissues post IA administration. The higher-than-1.5 AUC

Indexed as

ArthralgiaDexamethasoneOsteoarthritisProdrugsAnimalsDisease Models, AnimalInjections, Intra-ArticularMaleMiceTissue DistributionDexamethasoneProdrugsDexamethasoneOsteoarthritisPharmacokinetics and biodistributionProdrugThermoresponsive hydrogel

Identifiers

PMID41352407
PMCPMC13238187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.